Quantcast

Latest Prostate cancer Stories

2014-09-29 08:31:04

Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness REDWOOD CITY, Calif., Sept. 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University...

2014-09-29 08:29:46

Final data after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer presented at European Society for Medical Oncology (ESMO) 2014 Congress TORONTO, Sept. 29, 2014 /CNW/ - A final analysis of the Phase 3 COU-AA-302 trial presented at the European Society for Medical Oncology (ESMO) conference in Madrid, Spain showed that ZYTIGA(®) (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to...

2014-09-29 08:25:54

TORONTO, Sept. 29, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY -- Prostate Cancer Canada is in a race to give the approximately 24,000 Canadian men diagnosed with prostate cancer each year a better fighting chance. In response to the urgent need to increase the pace of discovery, Prostate Cancer Canada will be funding breakthrough research into a new generation of drugs that used alone or in combination with other therapies will...

Simple Blood Test Could Be Used As Tool For Early Cancer Diagnosis
2014-09-28 06:00:01

University of Bristol Hypercalcaemia is the most common metabolic disorder associated with cancer, occurring in 10 to 20 percent of people with cancer. While its connection to cancer is well known, this study has, for the first time, shown that often it can predate the diagnosis of cancer in primary care. A simple blood test could identify those with hypercalcaemia, prompting doctors to investigate further. The research, published in the British Journal of Cancer, analyzed the...

2014-09-28 08:21:14

Final analysis of Phase 3 COU-AA-302 study presented at the European Society for Medical Oncology (ESMO) 2014 Congress HORSHAM, Pa., Sept. 28, 2014 /PRNewswire/ -- A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA(®) (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men...

2014-09-27 08:21:15

- AbbVie presents preliminary data from randomized phase 2 trial of veliparib in non-small cell lung cancer NORTH CHICAGO, Ill., Sept. 27, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with...

2014-09-26 23:01:32

New genetic links to prostate cancer can identify men at higher risk and may lead to targeted screening, according to researchers at CPIC and colleagues. Fremont, CA (PRWEB) September 26, 2014 A major international study has identified 23 new genetic variants that are associated with an increased risk of developing prostate cancer, according to researchers at the Cancer Prevention Institute of California (CPIC) and their colleagues. With this new study, there are now 100 genetic variants...

2014-09-26 08:25:45

Results from First Clinical Study Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast Cancer Also Will Be Presented REDWOOD CITY, Calif., Sept. 26, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from a second large, independent clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ) will be featured as an oral presentation at the 37(th) Annual...

2014-09-25 23:02:30

The Reproductive Cancer Awareness Month affects both men and women. It is a great reminder to take care of ourselves and to take precaution when it comes to our health. Scotch Plains, NJ (PRWEB) September 25, 2014 September is recognized as “Reproductive Cancer Awareness Month” by many organizations, including the American Cancer Society (http://www.cancer.org/myacs...), in an effort to educate and inform the public. Ovarian and prostate cancer, two of the leading cancers in women...

2014-09-25 08:27:17

SAN DIEGO, Sept. 25, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostic laboratory testing. The agreement includes GenomeDx Biosciences' participation in the MultiPlan Network, expanding access to the Decipher(®) Prostate Cancer Classifier to health plan members who access the more than 500,000 providers participating in the MultiPlan Network. The Decipher prostate cancer classifier directly...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related